Welcome to CDC Stacks | Nationwide shortage of tuberculin skin test antigens : CDC recommendations for patient care and public health practice - 25254 | Health Alert Network (HAN)
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Nationwide shortage of tuberculin skin test antigens : CDC recommendations for patient care and public health practice
  • Published Date:
    4/12/13
  • Source:
    HAN ; 345
  • Language:
    English
Filetype[PDF - 1.34 MB]


Details:
  • Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
  • Series:
    HAN ; 345
  • Document Type:
  • Description:
    April 12, 2013, 11:00 EDT

    CDC HAN-00345

    TUBERSOL®, a product of Sanofi Pasteur Limited, is in shortage nationwide until at least the end of May 2013. TUBERSOL® is one of two purified-protein derivative (PPD) tuberculin products that are licensed by the United States Food and Drug Administration (FDA). The manufacturer notified CDC that 50-dose vials of TUBERSOL® are unavailable and that the supplies of 10-dose vials will be limited. This notice advises public health officials, clinicians, and workers in occupational health and infection control about how to adapt to the shortage.

    JHP Pharmaceuticals, LLC, the manufacturer of APLISOL®, the other PPD tuberculin product that is licensed by FDA, has notified FDA that the product is on allocation and is available in restricted quantity. Acute local shortages of APLISOL® are being reported to CDC by healthcare providers who switch from TUBERSOL® to APLISOL®.

  • Supporting Files:
    No Additional Files